Ketamine-Assisted Mindfulness Therapy Shows Promise for Opioid Use Disorder in Groundbreaking Clinical Trial

A person sits in a quiet room, headphones delivering guided meditation instructions while an IV slowly drips ketamine into their arm. Over the next hour, they'll practice mindfulness techniques designed to help them notice cravings without acting on them, reframe pain without reaching for opioids, and find moments of natural reward in a brain that's spent years seeking them only from drugs. Eight weeks later, they'll do it again. And again.

This is ketamine-assisted Mindfulness-Oriented Recovery Enhancement (MORE), and according to a randomized controlled trial published March 25 in Nature Mental Health, it may represent a breakthrough in treating opioid use disorder—a condition where existing medications work, but often not well enough, and where many people drop out of treatment before recovery takes hold.

The study, led by Dr. Eric Garland at the University of Utah's Center on Mindfulness and Integrative Health Intervention Development, enrolled 68 people already receiving buprenorphine for opioid use disorder. Half received eight weeks of MORE therapy via telehealth video sessions—learning mindfulness meditation, cognitive reappraisal strategies to reinterpret pain and craving, and techniques to savor natural pleasures. The other half received the same therapy plus three ketamine infusion sessions spaced across the eight weeks.

The results suggest ketamine doesn't just enhance the therapy—it may fundamentally change how the brain responds to it.

Why Medication Alone Isn't Enough

Buprenorphine has become the backbone of opioid addiction treatment in the United States. As a partial opioid agonist, it reduces cravings and withdrawal without producing euphoria, and research shows it cuts overdose risk by roughly 60 percent. Veterans Affairs data indicates 86.9 percent of patients remain in treatment at 90 days when starting buprenorphine.

Yet retention tells only part of the story. Many people who stay on buprenorphine continue to experience cravings, struggle with chronic pain that initially drove their opioid use, and find little pleasure in activities that used to bring joy—a condition researchers call anhedonia, where the brain's reward system remains fundamentally dysregulated even after opioid use stops.

This is where psychotherapy has traditionally stepped in, teaching coping skills and addressing underlying trauma. But adherence to psychosocial treatments for substance use disorders remains chronically low—a 2020 meta-analysis in Addiction found dropout rates averaging 40 percent across in-person programs. People leave because sessions feel repetitive, because talking about trauma is exhausting, because their brains are wired to seek relief in chemicals, not conversations.

Ketamine may change that equation.

The Neuroplasticity Window

Ketamine has spent the past decade moving from anesthetic to antidepressant, with FDA approval of its enantiomer esketamine (Spravato) for treatment-resistant depression in 2019. But research increasingly suggests ketamine's therapeutic potential extends beyond mood disorders into addiction—not because it replaces one drug with another, but because it appears to temporarily reopen what neuroscientists call critical periods of neuroplasticity.

A 2023 paper in Nature showed psychedelics including ketamine can reopen the social reward learning critical period in mice, allowing adult brains to relearn associations that were supposed to be fixed in adolescence. In humans, this manifests as what researchers describe as a temporary window where entrenched thought patterns become malleable, where people can reconsider their relationship to substances and pain without the usual cognitive rigidity.

Several small trials have tested this hypothesis. Dr. Elias Dakwar at Columbia found a single ketamine infusion combined with mindfulness-based behavioral modification significantly reduced cocaine use compared to midazolam placebo. Another trial showed ketamine plus relapse prevention therapy cut heavy drinking days in alcohol use disorder. Russian researchers reported in 2002 that ketamine psychotherapy for heroin addiction showed benefits at two-year follow-up, though that study lacked the methodological rigor of modern trials.

The mechanism remains under investigation. Ketamine acts primarily as an NMDA receptor antagonist, disrupting glutamate signaling in ways that promote synaptic growth and connectivity. It also activates mu-opioid receptors, raising concerns about abuse potential but potentially explaining why it helps with opioid-related anhedonia. And it reduces activity in the brain's default mode network—the system responsible for self-referential thinking and rumination that often keeps people stuck in cycles of shame and craving.

Dr. Garland's work with MORE therapy focuses precisely on interrupting these cycles. Mindfulness training teaches people to observe cravings without reacting, cognitive reappraisal helps reinterpret pain sensations, and savoring exercises rebuild the capacity for natural reward. But learning these skills requires neuroplasticity—the ability to form new neural pathways competing with the deeply ingrained circuits addiction has carved.

That's where ketamine comes in.

What the Trial Found

Participants in the Nature Mental Health study received buprenorphine maintenance therapy throughout—ketamine wasn't replacing medication, but augmenting it. The MORE-only group showed improvements in several measures, consistent with prior research showing mindfulness-based interventions help people on opioid agonist treatment. But the ketamine group showed more robust changes.

The study measured multiple outcomes: opioid craving intensity, depression and anxiety symptoms, self-reported opioid misuse, and importantly, subjective experiences during ketamine sessions using the Mystical Experience Questionnaire—a validated tool that assesses experiences of transcendence, unity, and ineffability that prior research links to better substance use outcomes.

Participants who reported stronger mystical-type experiences during ketamine sessions showed greater reductions in craving and more sustained engagement with mindfulness practices between sessions. This aligns with findings from psilocybin trials for alcohol and tobacco addiction, where the intensity of the psychedelic experience predicted long-term abstinence better than the drug dose itself.

The trial wasn't large enough to definitively prove ketamine plus MORE works better than MORE alone—at 68 participants, it was designed primarily to assess safety and preliminary efficacy. No serious adverse events occurred. Some participants experienced dissociation, nausea, and transient increases in blood pressure during infusions—expected effects that resolved within hours. Importantly, no one developed ketamine use disorder, a concern given that ketamine has abuse potential and participants had histories of addiction.

What the study does establish is proof of concept: combining ketamine with structured psychotherapy is feasible, appears safe in this population when delivered in controlled clinical settings, and produces signals suggesting enhanced therapeutic benefit compared to therapy alone.

The "Set and Setting" Question

Psychedelic researchers have long emphasized that these substances aren't magic bullets—context matters. The same drug that produces profound therapeutic insights in a supportive clinical environment can produce panic or psychosis when taken recreationally. Set (mindset, expectations, preparation) and setting (physical and social environment) determine whether a psychedelic experience becomes therapeutic or traumatic.

The MORE protocol built this principle into its design. Participants received extensive preparation before each ketamine session—learning mindfulness techniques, discussing intentions, building therapeutic rapport. During infusions, they listened to guided meditations specifically designed to direct attention toward natural rewards, reappraisal of pain, and letting go of craving. Therapists remained present throughout, providing reassurance when anxiety arose, gently redirecting attention when participants became absorbed in difficult material.

This stands in stark contrast to the uncontrolled ketamine use that occurs in illicit markets or even in some ketamine clinics that offer infusions without integrated psychotherapy. The trial's authors note that ketamine's dissociative effects—the sense of being detached from one's body and thoughts—may be essential to its therapeutic action, allowing people to observe their addiction from a distance rather than being consumed by it. But without guidance, dissociation can become frightening or meaningless.

The eight-week structure also matters. Participants received ketamine at weeks two, five, and eight—spaced sessions allowing time to integrate experiences and practice skills between infusions, rather than pursuing immediate relief through repeated dosing (which raises abuse risk). The telehealth delivery of weekly MORE sessions meant regular therapeutic contact, accountability, and ongoing support while the neuroplastic window remained open.

What Happens Next

Ketamine clinics have proliferated across the United States over the past five years, many offering infusions for depression, PTSD, and chronic pain with minimal psychotherapy integration. Some have begun advertising ketamine for addiction, capitalizing on early research and patient desperation. This trial provides the strongest evidence yet that ketamine may help opioid use disorder—but it also makes clear that ketamine alone isn't the answer. The therapy matters.

Whether insurance will cover ketamine-assisted psychotherapy for opioid use disorder remains uncertain. Medicaid and Medicare don't currently reimburse for psychedelic-assisted treatments except for FDA-approved esketamine (Spravato) for depression, which requires in-person administration and observation. The cost of three ketamine infusions plus eight therapy sessions would likely exceed $3,000 out of pocket—prohibitive for many people with opioid use disorder, who already face economic instability, housing insecurity, and barriers to accessing basic buprenorphine treatment.

Regulatory questions loom as well. Ketamine exists in a legal gray area: approved as an anesthetic but used off-label for psychiatric conditions, prescribed by physicians but administered in varied settings with inconsistent protocols. The DEA classifies it as a Schedule III controlled substance, less restricted than opioids but still requiring careful tracking. Some states have moved to regulate ketamine clinics more strictly after reports of adverse events and aggressive marketing.

The trial also leaves unanswered whether ketamine-assisted therapy works for people not already on buprenorphine—those who refuse opioid agonist treatment, who've tried and failed multiple medications, or who are still actively using illicit opioids. Including only people stabilized on buprenorphine made the study safer and more feasible, but limits generalizability to the broader population struggling with opioid addiction.

And crucially, the study tracked participants only through the eight-week intervention period. Whether benefits persist at six months, one year, or five years remains unknown. Relapse after treatment discharge is common with opioid use disorder—not because treatment doesn't work, but because the conditions driving addiction (trauma, poverty, social isolation, untreated pain) persist long after therapy ends.

The Bigger Picture

The opioid crisis has killed over 700,000 Americans since 2000. It emerged from aggressive pharmaceutical marketing of prescription painkillers, evolved through heroin, and metastasized with fentanyl—a synthetic 50 times stronger than heroin that now contaminates much of the illicit drug supply. Overdose deaths peaked around 2022 at over 1,500 per week, then began declining as naloxone became more widely available, as some fentanyl supply lines were disrupted, and as more people accessed medication-assisted treatment.

That decline represents progress, but it's fragile. Roughly 50 percent of people who start buprenorphine or methadone discontinue within a year. Many cycle in and out of treatment, stabilizing briefly before relapsing when stress, pain, or craving overwhelm their capacity to cope. Each return to use risks overdose in an era when fentanyl makes every street drug potentially lethal.

Improving retention in medication-assisted treatment by even small margins would save thousands of lives. If ketamine-assisted therapy helps more people stay engaged, reduces the suffering of persistent cravings and anhedonia, and rebuilds the neurological capacity for natural reward, it represents a meaningful advance—not a cure, but another tool.

The challenge will be ensuring that tool reaches the people who need it most. Psychedelic-assisted therapies risk becoming boutique treatments for affluent patients with access to specialty clinics and cash to pay out of pocket, while people in rural areas, people without insurance, people caught in the criminal justice system—those bearing the brunt of the opioid crisis—remain stuck with whatever underfunded services exist in their counties.

Dr. Garland's use of telehealth for the MORE component offers one model for expanding access, eliminating geographic barriers while maintaining therapeutic structure. But ketamine infusions still require in-person administration, medical monitoring, and clinics equipped to handle dissociative experiences safely.

Whether ketamine-assisted therapy becomes a standard component of opioid use disorder treatment or remains an experimental approach studied in academic medical centers will depend on questions beyond this single trial: larger studies confirming efficacy, insurance reimbursement decisions, regulatory frameworks balancing access with safety, and the willingness of addiction treatment systems to integrate approaches that look radically different from traditional counseling and medication management.

For now, 68 people received a treatment that may have changed the trajectory of their recovery. Some will relapse. Some will thrive. Some will remain on buprenorphine indefinitely, managing opioid use disorder as a chronic condition. Others may eventually taper off medication, their brains sufficiently rewired to sustain recovery without pharmaceutical support.

The trial can't predict individual outcomes. What it demonstrates is that pharmacologically reopening neuroplasticity, combined with skilled psychotherapy during that window, produces measurable changes in people for whom existing treatments weren't enough. Whether those changes endure, whether they can be replicated at scale, and whether the addiction treatment system will embrace a model requiring intensive clinical resources—these questions await answers.

But for a field where progress has come slowly, where people die waiting for better options, even preliminary evidence of a new approach that might work offers something increasingly scarce in the opioid crisis: a reason to hope that the brain's capacity for healing isn't exhausted, that neuroplasticity doesn't end in childhood, and that with the right combination of medicine, therapy, and timing, recovery becomes possible even when it seemed out of reach.